Current controversy: Triage of acute onset chest pain: now a biochemical rule-out test?

Area of Science:

• Cardiology
• Biomarker Technology
• Diagnostic Medicine

Background:

• Coronary disease management has advanced with sensitive blood biomarkers and structured assessments.
• Increased public awareness leads to many undiagnosed chest pain referrals for 'rule-out' evaluations.
• Urgent referrals are often based on managing unstable coronary disease, potentially delaying care for non-coronary patients.

Purpose of the Study:

• To evaluate the effectiveness of current chest pain management pathways.
• To question the over-reliance on biomarker assays for all chest pain presentations.
• To explore the role of traditional patient assessment and prior probability in diagnosis.

Main Methods:

• Review of current diagnostic pathways for chest pain.
• Discussion on the interpretation and specificity of cardiac biomarker assays.
• Consideration of the clinical utility and potential burden of 'rule-out' chest pain referrals.

Main Results:

• The effectiveness of current chest pain pathways, especially for non-coronary patients, is unclear.
• Superficial interpretation of non-specific tests can be misleading.
• The role of basic patient assessment and prior probability in diagnosing chest pain needs re-evaluation.

Conclusions:

• The universal application of biomarker assays for every chest pain patient is questioned.
• The diagnostic pathway for undiagnosed chest pain requires refinement to balance efficiency and accuracy.
• Further expert commentary is sought on cardiac biomarker technologies in managing chest pain dilemmas.